Work

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.

Year: 2021

Type: article

Abstract: compound mutations and CML stem cells. The clinical efficacy of this TKI combination needs to be evaluated within the frame of upcoming clinical trials.

Source: PubMed Central

Authors: Karoline V Gleixner, Yüksel Filik, Daniela Berger, Christina Schewzik, Gabriele Stefanzl, Irina Sadovnik, Lina Degenfeld-Schonburg, Gregor Eisenwort, Mathias Schneeweiss-Gleixner, Konstantin Byrgazov, Wolfgang R Sperr, Jiří Mayer, Thomas Lion, Peter Valent

Institutions: Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, St. Anna Children's Cancer Research Institute, Masaryk University, University Hospital Brno

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3207322437

FWCI: 5.45

Cites: 43

Cited by: 38

Related to: 10